Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VTGN

Vistagen Therapeutics (VTGN)

Vistagen Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VTGN
DateTimeSourceHeadlineSymbolCompany
06/11/20243:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
06/11/20243:27PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VTGNVistagen Therapeutics Inc
06/11/20243:20PMBusiness WireVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
06/11/20246:07AMIH Market NewsU.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices DeclineNASDAQ:VTGNVistagen Therapeutics Inc
06/07/20247:30AMBusiness WireVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024NASDAQ:VTGNVistagen Therapeutics Inc
05/31/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
05/29/20247:30AMBusiness WireVistagen to Present at the Jefferies Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
05/23/20247:30AMBusiness WireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
05/07/20247:30AMBusiness WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
04/25/20247:30AMBusiness WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistagen Therapeutics Inc
04/09/20247:30AMBusiness WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
04/01/20247:30AMBusiness WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2NASDAQ:VTGNVistagen Therapeutics Inc
03/11/20247:30AMBusiness WireVistagen to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VTGNVistagen Therapeutics Inc
03/06/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
03/06/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
03/06/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
03/06/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
02/29/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VTGNVistagen Therapeutics Inc
02/28/20247:30AMBusiness WireVistagen to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
02/14/20245:18PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
02/14/20243:51PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
02/14/20247:56AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
02/13/20243:52PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VTGNVistagen Therapeutics Inc
02/13/20243:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
02/13/20243:25PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
02/13/20243:20PMBusiness WireVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
02/12/20245:27PMEdgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
02/06/20247:30AMBusiness WireVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
01/03/20244:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
01/03/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VTGN

Your Recent History

Delayed Upgrade Clock